Pathogen Agnostic Sequencing

Detecting the Unknown. Connecting the Signals. Preparing for the Future.

What if we could recognize an emerging infectious disease before we knew what pathogen was causing it?

Advances in genomic sequencing, bioinformatics, and molecular diagnostics are creating new possibilities for detecting infectious diseases. Unlike traditional diagnostic approaches that generally require a known or suspected pathogen, pathogen-agnostic sequencing offers the potential to identify a broad range of organisms without requiring a predetermined microbial target.

The implications extend beyond clinical diagnostics to infectious-disease surveillance, outbreak investigation, emergency preparedness, and medical technology innovation.

What Is Pathogen-Agnostic Sequencing?

Traditional molecular diagnostic tests, such as targeted polymerase chain reaction (PCR) assays, are generally designed to detect specific organisms or defined groups of pathogens. Although these tests can be highly sensitive and reliable, they may not identify organisms outside their intended detection range.

Pathogen-agnostic sequencing takes a different approach. Metagenomic next-generation sequencing (mNGS), one of the principal technologies supporting this approach, examines genetic material within a specimen without requiring the selection of a specific pathogen in advance.

Depending on the sequencing method and analytical workflow, these technologies can detect genetic material associated with bacteria, viruses, fungi, parasites, and other organisms. Bioinformatics tools analyze the resulting sequences to identify potential pathogens, characterize genetic similarities, and investigate unfamiliar organisms.

Rather than asking whether a particular pathogen is present, pathogen-agnostic sequencing asks a broader question. What organisms may be present in this specimen?

How the Technology Works

Pathogen-agnostic sequencing involves several interconnected processes. It starts with specimen collection and preparation, obtaining and processing clinical or environmental specimens containing genetic material. Then, nucleic acid extraction recovers DNA or RNA and generate large quantities of genetic sequence data through genomic sequencing.

That is followed by a bioinformatics analysis that involves processing the sequence data, comparing it with reference databases, and investigating potentially unfamiliar sequences. Subsequent interpretation to determine the significance of the findings within their clinical or public health context.

The sequencing instrument is only one component of this process. Specimen quality, laboratory procedures, software performance, reference databases, and the interpretation of results all influence the reliability of the findings.

Applications in Healthcare and Public Health

Pathogen-agnostic sequencing has potential applications across several areas of healthcare and infectious-disease preparedness.

Clinical diagnostics. Investigating infections of unknown origin, particularly when conventional diagnostic testing has failed to identify a causative organism.

Emerging infectious diseases. Recognizing unusual or previously uncharacterized pathogens that may not be detected by existing targeted assays.

Outbreak investigation. Characterizing organisms and examining genetic relationships among infections to help investigate potential transmission patterns.

Environmental surveillance. Analyzing wastewater and other environmental specimens for biological signals that may indicate emerging public health threats.

Antimicrobial resistance. Identifying genetic markers associated with antimicrobial resistance, although genetic findings do not always establish an organism’s actual susceptibility.

These applications illustrate how sequencing technologies could complement existing diagnostic and surveillance systems rather than replace them.

From Genomic Sequences to Public Health Intelligence

Detecting genetic material associated with a pathogen is not the same as recognizing an emerging public health threat. Transforming sequencing data into actionable information requires laboratory networks, analytical capabilities, epidemiological expertise, data-sharing infrastructure, and mechanisms for communicating findings to healthcare providers and public health authorities.

Initiatives such as CDC’s Biothreat Radar reflect growing interest in integrating advanced molecular detection, genomic surveillance, wastewater monitoring, traveler-based surveillance, and data analytics to strengthen infectious-disease preparedness. The objective is to identify meaningful biological signals, assess their significance, and support an appropriate response before an emerging threat becomes a widespread public health emergency.

Scientific and Technical Challenges

Despite its potential, pathogen-agnostic sequencing presents important scientific and operational challenges. Human genetic material may overwhelm microbial sequences within clinical specimens. Contamination can produce misleading findings, while low concentrations of pathogens may limit detection. Reference databases may be incomplete, particularly for unfamiliar organisms.

Additional challenges include distinguishing clinically significant pathogens from harmless organisms or contaminants, establishing analytical sensitivity across diverse organisms and specimen types, interpreting unfamiliar or previously uncharacterized genetic sequences, maintaining reliable bioinformatics pipelines and reference databases, and managing testing costs, turnaround times, and computational requirements.

The detection of genetic material does not necessarily establish that an organism is viable, infectious, or responsible for a patient’s illness. Pathogen-agnostic sequencing is therefore a powerful investigative tool, but its findings require careful interpretation and, where appropriate, confirmation through additional testing.

The Emerging Regulatory Landscape

Pathogen-agnostic sequencing presents a distinctive challenge for medical device regulatory science. Conventional diagnostic performance studies generally evaluate a test against defined organisms and established reference methods. But how should manufacturers demonstrate the performance of a technology intended to detect a broad range of organisms, potentially including pathogens that have not yet been characterized?

Important regulatory considerations include intended use, analytical and clinical performance, specimen compatibility, contamination controls, bioinformatics validation, reference database management, software lifecycle controls, and result interpretation.

On November 19, 2026, FDA’s Microbiology Devices Panel is scheduled to examine pathogen-agnostic sequencing for emergency preparedness and response. The discussion highlights the importance of developing appropriate scientific and regulatory approaches for evaluating these emerging diagnostic technologies.

Implications for the Medical Device and Diagnostics Industries

The development of pathogen-agnostic sequencing technologies creates opportunities extending well beyond genomic sequencing instruments. The broader technology ecosystem includes

    • In vitro diagnostic systems and molecular detection technologies
    • Specimen collection, preservation, and preparation products
    • Laboratory automation and sample processing systems
    • Bioinformatics software and genomic reference databases
    • Artificial intelligence and analytical decision-support technologies
    • Data interoperability, cybersecurity, and laboratory information systems, and
    • Quality control materials and diagnostic performance assessment tools.

For manufacturers, these developments present opportunities for innovation alongside new challenges in product validation, quality management, regulatory compliance, and system integration.

Preparing for What Has Yet to Be Discovered

Pathogen-agnostic sequencing represents a shift toward broader, less target-dependent approaches to infectious-disease detection. Its greatest potential may lie in complementing existing diagnostic and surveillance capabilities, particularly when healthcare providers and public health authorities encounter unfamiliar biological threats.

Realizing that potential will require more than advances in sequencing technology. It will require reliable analytical systems, appropriate regulatory frameworks, coordinated public health infrastructure, and collaboration across government, academia, healthcare, and industry.

The ultimate objective is not simply to sequence more pathogens. It is to recognize an emerging threat early enough to change its course.

Intersurgical 22mm Smoothbore Breathing Tubes and Systems

FDA Issues Early Alert for Intersurgical Breathing Systems Over Potential Ventilation Failure. Manufacturing defect may cause breathing tube connectors to separate during use, potentially interrupting ventilation and exposing patients to serious injury or death.The...

FDA Early Alert: Teleflex/Arrow Guidewire

Affected guidewires and catheter products may release hydrophilic polymer particles into the bloodstream, potentially causing serious injury or death. No serious injuries or deaths have been reported.The U.S. Food and Drug Administration (FDA) has issued an Early...

FDA Requires New GLP-1 Drug Warning for Vision Loss Risk

Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...

Class 1 Recall for HemosIL AcuStar HIT Antibody Test

HemosIL AcuStar HIT-IgG(PF4-H). Source: fda.govPerformance problems could produce false-negative results, potentially delaying diagnosis of a dangerous reaction to heparin.The U.S. Food and Drug Administration (FDA) has identified a recall of certain lots of the...

FDA Approves Amplatzer Paraclose for Heart Valve Leaks

Abbott's Amplatzer Paraclose PVL Occluder offers a minimally invasive alternative for patients who develop a significant complication following heart valve replacement surgery.Heart valve replacement surgery can be lifesaving for patients with damaged or diseased...

October 2026 Premarket Approval (PMA) Authorizations

Three original device approvals and 218 supplements / noticesFDA's October activity highlights three newly approved medical devices and the extensive regulatory oversight required to maintain and modify products already on the market.The U.S. Food and Drug...

A Heart Valve Designed to Grow with Children

The new pediatric heart valve could reduce the need for repeat surgeries, but FDA requires additional studies to establish its long-term benefits.Children born with certain heart conditions may face multiple surgeries as they grow. One reason is surprisingly simple:...

FDA Clears AI Software for Automated Kidney Volume Assessment

AIRA uses artificial intelligence to analyze CT images and measure kidney volume, offering clinicians an automated tool for renal assessment. FDA Authorization Item Information Device Artificial Intelligence Renal Assessment (AIRA) Version 1 Manufacturer Aramis Global...

FDA Approves SELUTION SLR Drug-Eluting Balloon

SELUTION SLR Drug-Eluting Balloon. Source: MedAlliance LLCNew PMA approval introduces a sirolimus-eluting balloon treatment for coronary arteries, supported by randomized clinical evidence and ongoing post-approval surveillance. FDA approved the SELUTION SLR™ 014 PTCA...

Major Quality System Failures at Cardiac Device Manufacturer

Agency cites device classification disputes, inadequate manufacturing controls, and quality system deficiencies dating back to 2011An August 26, 2026, FDA warning letter to Peter Schiff Enterprises, a Tennessee manufacturer of cardiac devices, describes a troubling...

Pharma Innovation
Medical Devices